Type of surgery in rectal gastrointestinal stromal tumour (GIST) does not affect outcome in a large european cohort
Nikki S. IJzerman(Erasmus MC), Yvonne Schrage(The Netherlands Cancer Institute), Myles Smith(Royal Marsden NHS Foundation Trust), Marco Fiore(Fondazione IRCCS Istituto Nazionale dei Tumori), Hans Gelderblom(Leiden University Medical Center), Neeltje Steeghs(Peter MacCallum Cancer Centre), Sylvie Bonvalot(Dana-Farber Cancer Institute), Jos A. van der Hage(Leiden University Medical Center), Charles Honoré(Institut Gustave Roussy), Mahmoud Mohammadi(Leiden University Medical Center), Elżbieta Bylina(The Maria Sklodowska-Curie National Research Institute of Oncology), Winan J. van Houdt(Diakonessenhuis hospital), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Paris Tekkis(Imperial College London), Dirk J. Grünhagen(Erasmus MC), Han J. Bonenkamp(Radboud University Nijmegen), John Zavrakidis(The Netherlands Cancer Institute), Boudewijn van Etten(University Medical Center Groningen), Dimitri Tzanis(Université Paris Cité)
Cited by 0
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k